News | Heart Failure | January 26, 2017

Novel Tests Could Improve Treatment for Heart Failure Patients

Researchers find new methods can detect heart failure with greater accuracy, catch onset of congestive heart failure sooner

novel blood tests, improved treatment, heart failure patients, Clinical Chemistry, AACC

January 26, 2017 — For the first time, researchers have developed tests that could improve treatment for heart failure patients by diagnosing the condition with greater accuracy and detecting the onset of congestive heart failure earlier. The findings were published in the Cardiovascular Disease issue of Clinical Chemistry, the journal of the American Association for Clinical Chemistry (AACC).

Heart failure occurs when the heart is weakened and can no longer pump blood adequately. There are numerous conditions that can damage the heart muscle and lead to heart failure, from coronary artery disease to diabetes to drug abuse, and in the United States, it is the leading cause of hospitalization for people older than age 65. At present, the main blood tests used to aid in the diagnosis of heart failure are those for B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide (NT-proBNP). However, natriuretic peptide tests have a high false-positive rate and a limited ability to detect the early and asymptomatic stages of the disease.

With the goal of overcoming the drawbacks of current heart failure tests, a group of researchers developed a diagnostic panel that provides a more comprehensive representation of the heart’s functioning by measuring multiple biological molecules. Led by Hugo A. Katus, M.D., Ph.D., of Heidelberg University Hospital in Heidelberg, Germany, the researchers began by identifying 92 metabolites — byproducts of the body’s metabolism — that changed significantly in heart failure patients compared with healthy individuals. They chose three of these metabolites that belong to the lipid classes of sphingomyelins, triglycerides and phosphatidylcholines for their cardiac lipid panel (CLP).1

In a second confirmation study, the researchers then tested the ability of CLP combined with NT-proBNP measurements to diagnose heart failure in 649 individuals who either had the condition, were healthy or had pulmonary diseases (which can often be confused with heart failure). CLP plus NT-proBNP diagnosed heart failure with much greater certainty than NT-proBNP alone, even in the early and asymptomatic stages, demonstrating a high specificity of 97.6 percent, while NT-proBNP by itself only has a specificity of 88.1 percent.

“A low false-positive rate is particularly important in the outpatient setting and may prevent patients from unnecessary diagnostic workup and treatment, which in turn will save resources and avoid potential side-effects,” said Katus. “A more accurate diagnosis of patients with early and intermediate […] and mild or asymptomatic systolic dysfunction as observed with the novel panel compared to NT-proBNP alone may accelerate adequate pharmacological or behavioral treatments for the reduction of mortality and morbidity in these patients.”

Heart failure can also progress to congestive heart failure, which occurs when fluid builds up in the limbs, lungs and/or other organs as an indirect result of the heart’s weakened pumping. Systemic congestion is a major determinant of organ dysfunction and death in chronic heart failure patients. Currently, there is no reliable test that can diagnose congestion in its pre-symptomatic stages, which is needed so that healthcare providers can start or adjust decongestive therapy for patients before the condition worsens.

In this paper2, a group of researchers led by Alexandre Mebazaa, M.D., of Université Paris Diderot, show that a test for the protein-soluble CD146 (sCD146) could potentially detect congestion early. One of the initial signs of congestion is a subclinical increase of venous pressures. To demonstrate that sCD146 is released as a response to this, the researchers compressed the dominant arm of 44 stable chronic heart failure patients and measured sCD146 levels in both arms at the start time and after 90 minutes. In the compressed arm, sCD146 levels increased significantly by 60 µg/L compared with a small 16 µg/L increase in the control arm. These results indicate that, if validated in larger studies, sCD146 could serve as a marker of the increased venous pressure that signals the onset of congestion.

For more information:


1. Mueller-Hennessen, M., Dungen, H-D., Lutz, M., Trippel, T.D., et al. "A Novel Lipid Biomarker Panel for the Detection of Heart Failure with Reduced Ejection Fraction," Clinical Chemistry. Published online Dec. 30, 2016. DOI: 10.1373/clinchem.2016.257279

2. Arrigo, M., Truong, Q.A., Onat, D., Szymonifka, J., et al. "Soluble CD146 Is a Novel Marker of Systemic Congestion in Heart Failure Patients: An Experimental Mechanistic and Transcardiac Clinical Study," Clinical Chemistry. Published online Dec. 30, 2016. DOI: 10.1373/clinchem.2016.260471

Related Content

Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init